Literature DB >> 9604803

Identification of new mutations in primary hyperoxaluria type 1 (PH1).

C von Schnakenburg1, G Rumsby.   

Abstract

Primary hyperoxaluria type 1 (PH1) is caused by deficiency of the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT). The AGXT gene, which codes for the 392 amino acid protein, has been mapped to chromosome 2q37.3. In order to identify new mutations in the AGXT gene we studied 79 PH1 patients using single strand conformation polymorphism analysis. In addition to a cluster of new mutations in exon 7 we report five novel mutations in exons 2, 4, 5, 9 and 10. These are T444C, G640A, G690A, 1008-1010delGCG and G1171A. These five new mutations contribute to our knowledge of the AGXT gene. Their possible consequences for PH1 phenotype and enzyme activity are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604803

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  3 in total

Review 1.  Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries.

Authors:  Jamsheer Jehangir Talati; Sally-Anne Hulton; Sander F Garrelfs; Wajahat Aziz; Shoaib Rao; Amanullah Memon; Zafar Nazir; Raziuddin Biyabani; Saqib Qazi; Iqbal Azam; Aysha Habib Khan; Jamil Ahmed; Lena Jafri; Mohammad Zeeshan
Journal:  Urolithiasis       Date:  2017-06-28       Impact factor: 3.436

2.  Biochemical analyses are instrumental in identifying the impact of mutations on holo and/or apo-forms and on the region(s) of alanine:glyoxylate aminotransferase variants associated with primary hyperoxaluria type I.

Authors:  Elisa Oppici; Riccardo Montioli; Antonio Lorenzetto; Silvia Bianconi; Carla Borri Voltattorni; Barbara Cellini
Journal:  Mol Genet Metab       Date:  2011-10-05       Impact factor: 4.797

3.  Mutational analysis of AGXT in two Chinese families with primary hyperoxaluria type 1.

Authors:  Guo-min Li; Hong Xu; Qian Shen; Yi-nv Gong; Xiao-yan Fang; Li Sun; Hai-mei Liu; Yu An
Journal:  BMC Nephrol       Date:  2014-06-17       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.